QUOTE AND NEWS
SeekingAlpha  Sep 4  Comment 
By Mark Kroenke: Antibiotic resistance is a problem. There is no question that novel compounds are needed, and Congress has attempted to jump start development of new anti-infectives by passing the GAIN act which went into effect October 1st,...
SeekingAlpha  Jul 29  Comment 
By Michael Vascocu: There are still many big catalysts ahead and closer to the end of the year that will propel the stock price much higher Back in May, I wrote a very thorough article on the potential of the IL-12 therapy that Ziopharm...
SeekingAlpha  Jul 29  Comment 
By Mark Kroenke: During their June 25th presentation at the JMP Securities Healthcare Conference (audio file), Dr. Lewis and Dr. Lebel spent a good chunk of their time discussing "the power of the platform" and Ziopharm's (NASDAQ:ZIOP) budding...
FierceBiotech  Jul 22  Comment 
Proving once again that CAR-T is now one of the hottest fields in cancer drug development, Boston-based Ziopharm Oncology is expanding its R&D collaboration with Intrexon to include the personalized immuno-oncology technology.
Benzinga  Jul 22  Comment 
ZIOPHARM Oncology, Inc. ("ZIOPHARM") (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the expansion of synthetic immuno-oncology programs in conjunction with...
SeekingAlpha  Jul 14  Comment 
By Diamond Technology Management: Situation: Ziopharm is an interesting concept based biotechnology investment. However, given the high short interest and high cost of borrowing shares(30% at popular brokerage), Ziopharm may be an interesting...
SeekingAlpha  Jun 15  Comment 
By Mark Kroenke: I was long Ziopharm Oncology (ZIOP) from sometime in 2009 until around April 2013. I believed palifosfamide would improve progression free survival in sarcoma patients, the drug would get approved, and ZIOP could use that revenue...
SeekingAlpha  May 28  Comment 
By Michael Vascocu: This year will be a pivotal and likely very successful year for the company: First off, Ziopharm is scheduled to have final data completed for primary outcome measure in June 2014 on Human IL-12 to treat melanoma. The main...
SeekingAlpha  May 23  Comment 
By Mark Kroenke: Ziopharm Oncology (ZIOP) currently has a market cap of around $300M-$350M, according to Yahoo Finance. Yahoo rarely gets these numbers exactly right, but let's assume $300M is in the right ballpark. For about $3/share, you can get...
StreetInsider.com  May 22  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ZIOPHARM+Oncology%2C+Inc.+%28ZIOP%29+Issues+Encouraging+Update+on+Ad-RTS-IL-12/9517615.html for the full story.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki